Evidence map›Paper›PMID 32349352›Full record

ArticleCancers2020

Mevalonate Pathway Enzyme HMGCS1 Contributes to Gastric Cancer Progression.

I-Han Wang, Tzu-Ting Huang, Ji-Lin Chen, Li-Wei Chu, Yueh-Hsin Ping, Kai-Wen Hsu, Kuo-Hung Huang, Wen-Liang Fang, Hsin-Chen Lee, Chian-Feng Chen and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

I-Han WangProgram in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei 112, Taiwan.
Tzu-Ting HuangInstitute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Ji-Lin ChenInstitute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Li-Wei ChuDepartment and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Yueh-Hsin PingDepartment and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Kai-Wen HsuResearch Center for Tumor Medical Science, China Medical University, Taichung 404, Taiwan.
Kuo-Hung HuangInstitute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Wen-Liang FangInstitute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
Hsin-Chen LeeDepartment and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.ORCID 0000-0001-7455-9593
Chian-Feng ChenCancer Progression Research Center, National Yang-Ming University, Taipei 112, Taiwan.ORCID 0000-0002-4906-7949
Chen-Chung LiaoProteomics Research Center, National Yang-Ming University, Taipei 112, Taiwan.
Rong-Hong HsiehSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110, Taiwan.
Tien-Shun YehInstitute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
National Yang Ming Chiao Tung University · TWChina Medical University · TWTaipei Medical University · TW

Funding

Ministry of Education (MOE) in Taiwan Cancer Progression Research Center, National Yang-Ming UniversityMinistry of Science and Technology, Taiwan MOST 107-2320-B-010-032
6 · The paper itself

Abstract

The 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) is a potential regulatory node in the mevalonate pathway that is frequently dysregulated in tumors. This study found that HMGCS1 expression is upregulated in stomach adenocarcinoma samples of patients and tumorspheres of gastric cancer cells. HMGCS1 elevates the expression levels of the pluripotency genes Oct4 and SOX-2 and contributes to tumorsphere formation ability in gastric cancer cells. HMGCS1 also promotes in vitro cell growth and progression and the in vivo tumor growth and lung metastasis of gastric cancer cells. After blocking the mevalonate pathway by statin and dipyridamole, HMGCS1 exerts nonmetabolic functions in enhancing gastric cancer progression. Furthermore, the level and nuclear translocation of HMGCS1 in gastric cancer cells are induced by serum deprivation. HMGCS1 binds to and activates Oct4 and SOX-2 promoters. HMGCS1 also enhances the integrated stress response (ISR) and interacts with the endoplasmic reticulum (ER) stress transducer protein kinase RNA-like endoplasmic reticulum kinase (PERK). Our results reveal that HMGCS1 contributes to gastric cancer progression in both metabolic and nonmetabolic manners.

Indexed as

gastric cancer progressionHMGCS1integrated stress responsemevalonate pathwaypluripotency

Identifiers

PMID32349352
PMCPMC7281414
OpenAlexW3018726026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.